“The EACH Coalition is dedicated to lowering drug costs for patients; however, we are concerned that price limits have little direct impact on patient costs and could ultimately limit patient access to needed medications through increased utilization management.
“We urge CMS to closely monitor the ultimate impact the drug price negotiations will have on patients and look forward to continue engaging directly with regulators to share patient perspectives and feedback throughout the process. We further urge all policymakers to reject further expansions of the negotiation program until more is known about the ultimate patient impact.”
The statement comes in follow-up to a comment letter submitted by the EACH Coalition to CMS on the latest guidance on the Medicare Drug Price Negotiation Program.